The



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Hua Tang et al.

Application No.: 10/695,291

Filed: October 28, 2003

For: PROPOFOL WITH CYSTEINE

Atty. Docket No.: TPIP021

Examiner: Unassigned

Group: 1614

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Assistant Commissioner for Patents, PO Box 1450, Alexandria, VA 22313 on

Signed: (acqui h. Vo

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§1.56 AND 1.97(c)

Assistant Commissioner for Patents PO Box 1450 Alexandria, VA 22313

Dear Sir:

The references listed in the attached PTO Form 1449, copies of which are attached, may be material to examination of the above-identified patent application. Applicants submit these references in compliance with their duty of disclosure pursuant to 37 CFR §§1.56 and 1.97. The Examiner is requested to make these references of official record in this application.

This Information Disclosure Statement is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that these references indeed constitute prior art.

This Information Disclosure Statement is believed to be filed before the mailing date of a first Office Action on the merits. Accordingly, it is believed that no fees are due in connection with the filing of this Information Disclosure Statement. However, if it is determined that any fees are due, the Commissioner is hereby authorized to charge such fees to Deposit Account No. 50-2626(Order No. TPIP021).

Respectfully submitted,

Paul Burgess Reg. No. 53,852

Transform Pharmaceuticals, Inc. 29 Hartwell Avenue Lexington, MA 02421



m 1449 (Modified)

Information Disclosure Statement By Applicant Atty Docket No.

TPIP021

Application No.:

10/695,291

Inventor Group

Hua Tang et al. 1614

Filing Date

(Use Several Sheets if Necessary)

October 28, 2003

U.S. Patent Documents

Examiner						Sub-	Filing
Initial	No.	Patent/ Pub	Date	Patentee	Class	Class	Date
		No.					
	Α	2003/0173547	11/21/2002	Jones et al.			
	В	2003/0165544	9/4/2003	Mishra et al.			
	С	4,056,635	11/1/1977	Glen et al.			
	D	4,452,817	6/5/1984	Glen et al.			
	Е	4,798,846	1/17/1989	Glen et al.			
	F	5,637,625	6/10/1997	Haynes			
	G	5,731,355	3/24/1998	Jones et al.			
	Н	6,028,108	2/22/2000	George			
	I	6,100,302	8/8/2000	Pejaver et al.			
	J	6,140,373	10/31/2000	May et al.			
	K	6,140,374	10/31/2000	May et al.			
	L	6,147,122	11/14/2000	Mirejovsky et al.			
	M	6,150,423	11/21/2000	Carpenter			
	N	6,177,477	1/23/2001	George et al.			
	0	6,534,547	3/18/2003	Carpenter			
	P	6,399,087	6/4/2002	Zhang et al.			

Foreign Patent or Published Foreign Patent Application

Examiner		Document	Publication	Country or		Sub-	Trans	slation
Initial	No.	No.	Date	Patent Office	Class	class	Yes	No
	Q	96/29064	9/26/1996	WO				
	R	01/89474	11/29/2001	WO				
	S	01/89514	11/29/2001	WO				

Other Documents

Examiner		
Initial	No.	Author, Title, Date, Place (e.g. Journal) of Publication
	T	Wachowski, Ireneusz et al., "The Growth of Microorganisms in Propofol and Mixtures of Propofol and Lidocaine", International Anesthesia Research Society, Anesth Analg 1999;88: 209-212

MAY 1 3 200	JC26				
THE TRADE!	<i>M</i> U		Han, Jihong et al., "Physical Properties and Stability of Two Emulsion Formulations of Propofol" International Journal of Pharmaceutics 21 (2001) pgs. 207-220		
	Examiner		Date Considered		

Examiner: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.